| $370M | ||
| $337M | ||
| $100M | ||
| $82M | ||
| $62M | ||
| $60M |
Buys | $25,924 | 7 | 23 |
Sells | $2,217,909 | 23 | 77 |
| Horne William B. | director | 3 | $13,028 | 0 | $0 | $13,028 |
| AULT MILTON C III | 3 | $7,847 | 23 | $2.22M | $-2.21M | |
| Katzoff David J | Chief Financial Officer | 1 | $5,048 | 0 | $0 | $5,048 |
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Over the last 12 months, insiders at Alzamend Neuro, Inc. have bought $25,924 and sold $2.22M worth of Alzamend Neuro, Inc. stock.
On average, over the past 5 years, insiders at Alzamend Neuro, Inc. have bought $3.8M and sold $781,592 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Horne William B. (director) — $13,028. AULT MILTON C III () — $7,847. Katzoff David J (Chief Financial Officer) — $5,048.
The last purchase of 3,334 shares for transaction amount of $3,285 was made by Horne William B. (director) on 2025‑03‑26.
| 2025-10-09 | Sale | AULT MILTON C III | director | 20,397 0.6478% | $2.32 | $47,390 | -2.86% | |
| 2025-10-08 | Sale | AULT MILTON C III | director | 101,394 3.1113% | $2.44 | $247,158 | -2.85% | |
| 2025-10-07 | Sale | AULT MILTON C III | director | 57,379 1.8285% | $2.49 | $142,954 | -6.42% | |
| 2025-10-06 | Sale | AULT MILTON C III | director | 82,033 2.5039% | $2.45 | $201,268 | -5.12% | |
| 2025-10-03 | Sale | AULT MILTON C III | director | 65,903 2.153% | $2.44 | $160,889 | -3.21% | |
| 2025-10-02 | Sale | AULT MILTON C III | director | 20,686 0.6627% | $2.39 | $49,522 | -1.63% | |
| 2025-10-01 | Sale | AULT MILTON C III | director | 36,777 1.1559% | $2.35 | $86,378 | +1.37% | |
| 2025-09-30 | Sale | AULT MILTON C III | 3,566 0.1113% | $2.33 | $8,321 | +1.26% | ||
| 2025-09-29 | Sale | AULT MILTON C III | 38,324 1.1942% | $2.31 | $88,490 | +2.28% | ||
| 2025-09-26 | Sale | AULT MILTON C III | 37,738 1.1543% | $2.31 | $87,345 | -0.00% | ||
| 2025-09-25 | Sale | AULT MILTON C III | 14,628 0.4527% | $2.31 | $33,829 | +2.70% | ||
| 2025-09-24 | Sale | AULT MILTON C III | 39,140 1.2094% | $2.31 | $90,374 | +1.68% | ||
| 2025-09-23 | Sale | AULT MILTON C III | 43,238 1.3951% | $2.38 | $102,721 | -2.63% | ||
| 2025-09-19 | Sale | AULT MILTON C III | 77,009 2.4% | $2.35 | $180,856 | -3.03% | ||
| 2025-09-18 | Sale | AULT MILTON C III | 20,870 0.6586% | $2.47 | $51,493 | -4.56% | ||
| 2025-09-17 | Sale | AULT MILTON C III | 2,121 0.0663% | $2.45 | $5,204 | -3.99% | ||
| 2025-07-31 | Sale | AULT MILTON C III | 100,000 3.3996% | $2.22 | $221,550 | +6.67% | ||
| 2025-07-30 | Sale | AULT MILTON C III | 29,449 1.0136% | $2.51 | $73,982 | -4.82% | ||
| 2025-07-28 | Sale | AULT MILTON C III | 8,311 0.2781% | $2.68 | $22,314 | -13.36% | ||
| 2025-07-25 | Sale | AULT MILTON C III | 36,532 1.2347% | $2.90 | $105,855 | -18.92% |
| Horne William B. | director | 30000 0.9555% | $75,900.00 | 3 | 0 | |
| AULT MILTON C III | director | 8260 0.2631% | $20,897.80 | 108 | 27 | <0.0001% |
| Katzoff David J | Chief Financial Officer | 5540 0.1764% | $14,016.20 | 2 | 0 | |
| GUSTAFSON MARK | 60000 1.9109% | $151,800.00 | 0 | 2 | ||
| Jackman Stephan | Chief Executive Officer | 45500 1.4491% | $115,115.00 | 1 | 0 | |
| McGrath Lynne Fahey | director | 10000 0.3185% | $25,300.00 | 1 | 1 |
Alzamend Neuro, Inc. (ALZN) | $13,664,154 | 40 | -70.35% | $7.94M |
$1,029,337 | 36 | -28.38% | $6.74M | |
$1,138,733 | 28 | -4.94% | $7.02M | |
$29,635,355 | 27 | 9.05% | $8.16M | |
$63,749,694 | 24 | -12.24% | $5.97M | |
$53,355 | 19 | -41.05% | $9.84M | |
$1,556,551 | 15 | -25.43% | $7.63M | |
$8,079,884 | 14 | -43.20% | $8.33M | |
$742,412 | 14 | -50.36% | $6.06M | |
$941,975 | 12 | -10.74% | $8.12M | |
$139,855 | 11 | -32.84% | $9.7M | |
$90,087 | 9 | 20.06% | $7.12M | |
$104,979 | 8 | -28.55% | $7.93M | |
$8,971,546 | 8 | 6.18% | $5.99M | |
$57,653 | 4 | 22.31% | $6.65M | |
$28,395 | 3 | 3.48% | $8.85M | |
$1,057,000 | 3 | 5.27% | $10.5M | |
$4,423 | 2 | 3.27% | $8.18M | |
$75,000 | 1 | -30.67% | $7.96M |
| Increased Positions | 4 | +44.44% | 1,722 | +24.53% |
| Decreased Positions | 3 | -33.33% | 6,558 | -93.42% |
| New Positions | 2 | New | 1,699 | New |
| Sold Out Positions | 3 | Sold Out | 6,558 | Sold Out |
| Total Postitions | 10 | +11.11% | 2,184 | -68.89% |
| Ubs Group Ag | $2.00 | 0.03% | 902 | +902 | New | 2025-06-30 |
| Tower Research Capital Llc (Trc) | $2.00 | 0.03% | 797 | +797 | New | 2025-06-30 |
| Blackrock, Inc. | $1.00 | 0.02% | 441 | 0 | 0% | 2025-06-30 |
| Sbi Securities Co., Ltd. | $0 | <0.01% | 22 | +20 | +1,000% | 2025-06-30 |
| Bank Of America Corp /De/ | $0 | <0.01% | 19 | +3 | +18.75% | 2025-06-30 |
| Activest Wealth Management | $0 | 0% | 2 | 0 | 0% | 2025-06-30 |
| Harbor Investment Advisory, Llc | $0 | 0% | 1 | 0 | 0% | 2025-09-30 |
| Barclays Plc | $0 | 0% | 0 | -486 | Sold Out | 2025-06-30 |
| Truist Financial Corp | $0 | 0% | 0 | -1,722 | Sold Out | 2025-06-30 |
| Geode Capital Management, Llc | $0 | 0% | 0 | -4,350 | Sold Out | 2025-06-30 |